Study of Patients Aged 60 and Over with Acute Myeloid Leukemia Receiving Intensive Induction Therapy

What this Trial Is About

Researchers are studying patients aged 60 and older who have newly diagnosed or secondary acute myeloblastic leukemia AML and are suitable for intensive induction therapy. The study aims to understand the clinical and biological characteristics of AML in these patients and how these relate to their outcomes. AML is more common with increasing age, especially after 50, with a median diagnosis age near 70. Despite treatments aiming for remission, long-term survival in elderly patients remains limited. This observational study follows patients who receive intensive chemotherapy as their initial treatment when their general health and other conditions allow. The study collects data on the patients initial AML characteristics, the first line of AML treatment they receive, and tracks their overall survival up to five years. The study does not test new treatments but monitors standard intensive therapy outcomes. Participants will have their disease characteristics described within three months of diagnosis, their initial treatment recorded over 12 months, and their overall survival monitored for five years. The study involves collecting clinical and biological data to better understand AML in older adults. Participation includes agreement to data collection and follow-up to assess outcomes and survival over several years.

Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy